...
首页> 外文期刊>American journal of cardiovascular drugs: drugs, devices, and other interventions >The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics.
【24h】

The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics.

机译:用奥美沙坦美多西米密阻血管紧张素II对阻力血管重塑的保护作用(VIOS研究):基本原理和基线特征。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: The VIOS (Vascular Improvement with Olmesartan medoxomil Study) study is a randomized, parallel study to determine the relative effects of suppressing the renin-angiotensin system (RAS) with the angiotensin receptor antagonist olmesartan medoxomil versus suppressing sympathetic drive with the beta-adrenoceptor antagonist atenolol on remodeling of the subcutaneous small resistance vessel. Remodeling of small resistance vessels may be the earliest pathologic finding associated with hypertension. It may predate the onset of clinically apparent hypertension. METHODS: In this study, 100 patients with stage I hypertension are characterized at baseline before being treated for 1 year to obtain a goal BP of less than 140/90 mm Hg as defined by Joint National Committee (JNC)-7. Resistance vessel remodeling is determined using the gluteal fat biopsy technique in the hypertensive patients and a group of normotensive healthy volunteers. Additionally, efforts will be made to define whether noninvasive hemodynamic parameters, retinal vessel measurement changes, or biologic markers may predict and track the underlying vascular morphologic and physiologic changes induced by either regimen during the 12-month treatment period. RESULTS: The primary endpoint will be the degree of vascular remodeling as obtained from percutaneous biopsy of gluteal subcutaneous resistance vessels in each of two treatment arms compared with the normal volunteers. The design of the study and the pertinent baseline characteristics of these patients with uncomplicated essential hypertension are presented. CONCLUSION: The suppression of the RAS by the blockade of angiotensin II type 1 (AT(1)) receptors may demonstrate remodeling effects on the ubiquitous small resistance vessels similar to that seen in the myocardium and renal glomeruli, thus affording more complete end-organ protection.
机译:背景:VIOS(奥美沙坦美索莫米研究对血管的改善)研究是一项随机平行研究,旨在确定用血管紧张素受体拮抗剂奥美沙坦美托索米尔抑制肾素-血管紧张素系统(RAS)与用β-肾上腺素受体抑制交感神经驱动的相对作用拮抗剂阿替洛尔对皮下小阻力血管的重塑。小阻力血管的重塑可能是与高血压相关的最早病理发现。它可能早于临床上明显的高血压发作。方法:在这项研究中,对100例I期高血压患者进行了1年基线治疗,以达到国家联合委员会(JNC)-7定义的目标BP低于140/90 mm Hg的目标。在高血压患者和一组血压正常的健康志愿者中,使用臀脂活检技术确定了抵抗血管的重塑。另外,将努力确定在12个月的治疗期间,无创血液动力学参数,视网膜血管测量变化或生物标志物是否可以预测和跟踪由任何一种疗法引起的潜在血管形态和生理变化。结果:主要终点将是与正常志愿者相比,从两个治疗组中的每组的臀肌皮下阻力血管的经皮活检中获得的血管重塑程度。介绍了研究的设计以及这些并发原发性高血压患者的相关基线特征。结论:通过阻断血管紧张素II 1型(AT(1))受体抑制RAS可能显示出对无处不在的小阻力血管的重塑作用,类似于在心肌和肾小球中观察到的,从而提供了更完整的终末器官保护。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号